| |
Units
|
Total
|
Attack
|
Remission
|
Acute MY subgroup
|
Acute ON subgroup
|
Acute BRAIN subgroup
|
|---|
|
Intrathecal IgM synthesis
|
|
QIgM > Qlim(IgM)
|
Samples
|
13/112 (12%)
|
13/84 (15%)
|
0/20 (0%)
|
9/38 (24%)
|
3/39 (8%)
|
1/6 (17%)
|
|
QIgM, all LPs
|
-
|
0.5 (0-13.8; 111)
|
0.6 (0-13.8; 83)
|
0.5 (0-4.1; 20)
|
1.11 (0-13.81; 38)
|
0.41 (0-1.82; 38)
|
0.28 (0-1.9; 6)
|
|
QIgM, if positive
|
-
|
1.9 (0.6-9.6; 13)
|
1.9 (0.6-9.6; 13)
|
n.a.
|
2.72 (0.63-9.63; 9)
|
0.84 (0.68-1.33; 3)
|
1.9 (1.9-1.9; 1)
|
|
IgM IF, all LPs
|
% IgM (CSF)
|
0 (0-59.1; 111)
|
0 (0-59.1; 83)
|
0 (0-0; 20)
|
0 (0-59.1; 38)
|
0 (0-41.9; 38)
|
0 (0-18.3; 6)
|
|
IgM IF, QIgM positives
|
% IgM (CSF)
|
9.2 (1-59.1; 13)
|
9.2 (1-59.1; 13)
|
n.a. (n.a.;0)
|
9.2 (3.5-59.1; 9)
|
9 (1-41.9; 3)
|
18.3 (18.3-18.3; 1)
|
|
IgM IF, > 10%
|
Samples
|
6/111 (5.4%)
|
6/83 (7.2%)
|
0/20 (0%)
|
4/38 (10.5%)
|
1/38 (2.6%)
|
1/6 (16.7%)
|
|
IgM Loc, all LPs
|
mg/l
|
0 (0-2.3; 108)
|
0 (0-2.3; 81)
|
0 (0-0; 19)
|
0 (0-2.3; 36)
|
0 (0-0.3; 38)
|
0 (0-0.6;6)
|
|
IgM Loc, QIgM positives
|
mg/l
|
0.32 (0.01-2.3; 13)
|
0.32 (0.01-2.3; 13)
|
n.a.
|
0.3 (0.1-2.3; 9)
|
0 (0-0.3; 3)
|
0.6 (0.6-0.6; 1)
|
|
IgM CSF
|
mg/l
|
0.5 (0-16.3; 110)
|
0.5 (0-16.3; 82)
|
0.49 (0-3.6; 19)
|
1.69 (0-16.3; 36)
|
0.36 (0-1.51; 39)
|
0.25 (0-4.19; 6)
|
|
IgM serum
|
g/l
|
1.02 (0.15-3.73; 112)
|
1.03 (0.15-3.73; 84)
|
0.89 (0.39-2.19; 20)
|
1.18 (0.3-2.96; 37)
|
0.94 (0.15-2.41; 40)
|
1 (0.79-3.73; 6)
|
|
Intrathecal IgA synthesis
|
|
QIgA > Qlim(IgA)
|
Samples
|
5/111 (5%)
|
4/83 (5%)
|
1/20 (5%)
|
2/38 (5.3%)
|
2/38 (5.3%)
|
0/6 (0%)
|
|
QIgA, all LPs
|
-
|
2 (0-17.3; 110)
|
1.9 (0-17.3; 82)
|
2.5 (0-11.1; 20)
|
2.65 (0-17.27; 38)
|
1.51 (0-3.22; 37)
|
2.15 (0-3.26; 6)
|
|
QIgA, if positive
|
-
|
2.6 (1.7-6.2; 5)
|
2.4 (1.7-6.2; 4)
|
2.9 (2.9-2.9; 1)
|
4.42 (2.61-6.24; 2)
|
1.96 (1.68_2.24; 2)
|
n.a. (n.a.; 0)
|
|
IgA IF, all LPs
|
% IgA (CSF)
|
0 (0-34.2; 110)
|
0 (0-31.7; 82)
|
0 (0-34.2; 20)
|
0 (0-31.7; 38)
|
0 (0-13.3; 37)
|
0 (0-0; 6)
|
|
IgA IF, QIgA positives
|
% IgA (CSF)
|
13.3 (3.8-34.2; 5)
|
9.5 (3.8-31.7; 4)
|
34.2 (34.2-34.2; 1)
|
17.8 (3.8-31.7; 2)
|
9.5 (5.7-13.3; 2)
|
n.a. (n.a.; 0)
|
|
IgA IF, > 10%
|
Samples
|
3/110 (2.7%)
|
2/82 (2.4%)
|
1/20 (5%)
|
1/38 (2.6%)
|
1/37 (2.7%)
|
0/6 (0%)
|
|
IgA Loc, all LPs
|
mg/l
|
0 (0-2.9; 106)
|
0 (0-2.9; 79)
|
0 (0-2; 19)
|
0 (0-2.9;36)
|
0 (0-0.5; 36)
|
0 (0-0; 6)
|
|
IgA Loc, QIgA positives
|
mg/l
|
0.5 (0.2-2.9; 5)
|
0.5 (0.2-2.9; 4)
|
2 (2-2; 1)
|
1.6 (0.4-2.9; 2)
|
0.4 (0.2-0.5; 2)
|
n.a. (n.a.; 0)
|
|
IgA CSF
|
mg/l
|
3.6 (0-40.7; 109)
|
3.57 (0-40.7; 81)
|
4.4 (0-29.1; 19)
|
4.34 (0-40.7; 36)
|
3.1 (0-7.99; 38)
|
3.4 (0-10.4; 6)
|
|
IgA serum
|
g/l
|
1.95 (0.25-7; 108)
|
1.8 (0.62-7; 81)
|
2.3 (1.1-3; 19)
|
1.77 (0.62-7; 37)
|
2.04 (0.73-5.16; 37)
|
1.94 (0.67-3.99; 6)
|
- Quotients, concentrations, and fractions are given as median and range
- QIgG/A/M CSF/serum IgG/A/M ratio; IgG/A/M IF intrathecally produced IgG/IgA/IgM fraction; IgG/A/M loc locally (intrathecally) produced IgG/A/M; LP lumbar puncture
